Through our committed advocacy network, AIM has helped secure substantial increased investment in Alzheimer’s and dementia research funding since the passage of the National Alzheimer’s Project Act (NAPA). Following a $100 million increase signed into law in March 2024, and added to current NIH spending, annual federal funding for Alzheimer’s research will be as much as $3.8 billion, up from under $500 million annually when NAPA was passed.

As a result of this unprecedented funding, scientists are able to work at a more rapid pace to advance basic disease knowledge, explore ways to reduce risk, uncover new biomarkers for early diagnosis and drug targeting, and develop potential treatments.

For decades, millions of Americans and their families have waited for improved, effective therapies for Alzheimer’s and other dementia. Around the globe, researchers are working to find solutions for those facing the crushing realities of this relentless disease.

Thanks to our tireless advocates, AIM helped achieve today’s unprecedented levels of Alzheimer’s research funding. This funding is directly empowering scientists to explore a wide variety of pathways that could yield promising new therapies for people living with Alzheimer’s in the future.

It’s an exciting time for Alzheimer’s and dementia research. At any given moment, discovery is happening. Learn more about these exciting developments in Realizing the National Plan to Address Alzheimer’s Disease: Leadership Toward Treatment and Prevention.